Evidence map›Paper›PMID 39256312›Full record

ArticleAnnals of surgical oncology2024

Isolated Limb Infusion for Limb-Threatening Sarcomas.

Shaliz Aflatooni, Michelle M Dugan, Aleena Boby, Helana Ghali, Danielle K DePalo, Syeda Mahrukh Hussnain Naqvi, John E Mullinax, Jonathan S Zager

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shaliz Aflatooni *University of South Florida Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
Michelle M Dugan *Cutaneous Oncology Department, Moffitt Cancer Center, Tampa, FL, USA.
Aleena BobyUniversity of South Florida Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
Helana GhaliUniversity of South Florida Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
Danielle K DePaloCutaneous Oncology Department, Moffitt Cancer Center, Tampa, FL, USA.
Syeda Mahrukh Hussnain NaqviDepartment of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, USA.
John E MullinaxSarcoma Department, Moffitt Cancer Center, Tampa, FL, USA.
Jonathan S ZagerCutaneous Oncology Department, Moffitt Cancer Center, Tampa, FL, USA. jonathan.zager@moffitt.org.ORCID http://orcid.org/0000-0002-6886-4468

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIsolated limb infusion (ILI) treats unresectable extremity malignancies with high-dose regional chemotherapy limited to the limb. This study assessed long-term outcomes after ILI for limb-threatening sarcomas.

methodsA retrospective review analyzed patients with an extremity sarcoma who underwent ILI with melphalan and dactinomycin from 2008 to 2023 at a single institution.

resultsThe study identified 61 patients (52.5% female; median age, 73 years; range, 20-94 years). Of these patients, 68.9% had lower-extremity disease. The median follow-up period was 6.9 years. The overall response rate was 48.3% (complete response [CR], 21.7%; partial response [PR], 26.7%), and the disease control rate (DCR: CR + PR + stable disease [SD]) was 65%. The median progression-free survival (PFS) for the patients with CR/PR/SD/progressive disease (PD) was respectively 16.8/9.6/4.8/2.4 months (P < 0.0001). The responders (CR + PR) had significantly longer PFS than the non-responders (SD + PD) (hazard ratio [HR], 6.3; 95% confidence interval [CI], 3.1-12.9; P < 0.001). The median in-field PFS times for CR/PR/SD/PD were respectively 16.8/12/4.8/2.4 months (P < 0.001). The responders had a significantly longer risk of in-field PFS than the non-responders (HR, 5.9; 95% CI 2.9-12.0; P < 0.001). The median distant relapse PFS for CR/PR/SD/PD was not reached (NR)/NR/44.4/40.8 months (P = 0.02). The responders had a significantly longer distant relapse PFS than the non-responders (HR, 2.7; range, 1.1-6.8; P = 0.04). The median overall survival (OS) was 8.6 years for the responders and 4.1 years for the non-responders (P = 0.02). The disease-specific survival (DSS) rates were 87% at 1 year, 71% at 3 years, and 64% at 5 years. The median DSS was not reached for the responders and was 4.1 years for the non-responders (P = 0.003). The limb salvage rates at 6 months were 85% at 1 year, 80% at 3 years, and 70% at 5 years. The patients with PD had a higher risk of requiring amputation than the patients with CR + PR + SD (HR, 3.0; 95% CI 1.0-8.7; P = 0.04).

conclusionsThe 5-year limb salvage rates after ILI are notably high, reaching 70%. After ILI, the responders had significantly better in-field and distant relapse PFS, OS, and DSS.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsChemotherapy, Cancer, Regional PerfusionDactinomycinExtremitiesMelphalanSarcomaAdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisRetrospective StudiesDactinomycinMelphalanExtremity sarcomaIsolated limb infusionLimb salvageLimb-threatening sarcomaRegional chemotherapyUnresectable extremity sarcoma

Identifiers

PMID39256312

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.